Proteoglycans (PGs) play many important roles in biology, contributing to the mechanical properties of tissues, helping to organize extracellular matrix components, and participating in signaling mechanisms related to mechanotransduction, cell differentiation, immune responses, and wound healing. Our lab has designed two different types of PG mimics: polyelectrolyte complex nanoparticles (PCNs) and PG-mimetic graft copolymers (GCs), both of which are prepared using naturally occurring glycosaminoglycans. This work evaluates the enzymatic stability of these PG mimics using hyaluronidases (I-S, IV-S, and II), chondroitinase ABC, and lysozyme, for PG mimics suspended in solution and adsorbed onto surfaces. Hyaluronan (HA)-and chondroitin sulfate (CS)-containing PG mimics are degraded by the hyaluronidases. PCNs prepared with CS and GCs prepared with heparin are the only CS-and HA-containing PG mimics protected from chondroitinase ABC. None of the materials are measurably degraded by lysozyme. Adsorption to polyelectrolyte multilayer surfaces protects PG mimics from degradation, compared to when PG mimics are combined with enzymes in solution; all surfaces are still intact after 21 days of enzyme exposure. This work reveals how the stability of PG mimics is controlled by both the composition and macromolecular assembly of the PG mimic and also by the size and specificity of the enzyme. Understanding and tuning these degradation susceptibilities are essential for advancing their applications in cardiovascular materials, orthopedic materials, and growth factor delivery applications.
Cardiovascular implant surfaces and blood-contacting components of extracorporeal blood circuits induce blood clot formation (thrombosis) and red blood cell lysis (hemolysis) when in contact with flowing whole blood. These complications are prevented by systemic drugs, such as anticoagulant and antiplatelet therapies, which may cause additional complications. Therefore, stable surfaces that locally inhibit blood coagulation and hemolysis at the blood−material interface are an important research goal. Biopolymer-based polyelectrolyte multilayer surface coatings (PEMs) can modulate blood−material interactions. Ultrathin PEMs have been proposed as blood-compatible surfaces, but the mechanical stability of these nanoscale surfaces against shear forces has yet to be evaluated. Herein, we evaluated the mechanical durability of biomimetic PEM surfaces against shear flow and further modified these surfaces with polydopamine (PDA) and carbodiimide cross-linking to improve stability. The PDA-modified and cross-linked PEMs were more stable than unmodified PEMs. PDA-containing and cross-linked surfaces were compared to PEMs modified with proteoglycan mimetic nanoparticles and graft copolymers, which we have previously used to improve blood−material interactions. To evaluate hemocompatibility, we also performed whole blood clotting, thromboelastography, and hemolysis studies. All of the tested surfaces reduce clot formation when in contact with whole human blood. Modifying PEMs with PDA and amide cross-links improves their stability but does not significantly influence blood−material interactions. All of the surfaces prevent blood clotting when in direct contact with blood, indicating localized anticlotting activity. Only surfaces containing heparin nanoparticles and graft copolymers also reduce blood clotting or inhibit clot formation altogether in blood previously exposed to the surfaces, indicating potential systemic anticoagulant activity. PEMs are a versatile platform for developing blood-contacting materials, which are amenable to modifications that both increase mechanical stability and improve hemocompatibility.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.